A detailed history of Sherbrooke Park Advisers LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 23,363 shares of TGTX stock, worth $751,354. This represents 0.13% of its overall portfolio holdings.

Number of Shares
23,363
Previous 24,662 5.27%
Holding current value
$751,354
Previous $439 Million 24.55%
% of portfolio
0.13%
Previous 0.08%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.21 - $25.28 $22,355 - $32,838
-1,299 Reduced 5.27%
23,363 $546 Million
Q2 2024

Aug 14, 2024

BUY
$13.32 - $19.19 $328,497 - $473,263
24,662 New
24,662 $439 Million
Q3 2023

Nov 14, 2023

BUY
$8.36 - $26.5 $103,789 - $328,997
12,415 New
12,415 $104 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.67B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.